Better Therapeutics, a prescription digital therapeutic (PDT) startup, has announced a private placement of approximately USD 6.5 million through the sale of 7.9 million common shares at USD 0.825 per share. The financing was supported by certain officers and directors of the company. The private placement is expected to close on April 10, 2023.
The proceeds will be used to finance key milestones and extend the company's runway until the anticipated FDA commercialization authorization of BT-001 and the conclusion of additional strategic activities.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.